- Jul 30, 2007
- 8,421
- 75
- 0
- School/Org
- Newsbot U
- City
- Barre
- State
- VT

The relative risk is incredibly small, since the base was small. I would say for many people the systemic benefits far outweigh the risk, especially if someone is morbidly obese.The increase was from 0.1% to 0.2%. So double, but still very small.
Don't you mean absolute risk? The relative risk doubled, the absolute risk is small.The relative risk is incredibly small, since the base was small. I would say for many people the systemic benefits far outweigh the risk, especially if someone is morbidly obese.
Just as you Adam predict AI has problems as well as good I believe long term more and more problems and health concerns with emerge from GPL1 drugs. Yes they may help type II diabetics more then hurt but for the general population who take it to be stick figures watch out for those long term effects. You are changing basic function of the GI system " GLP-1, leading to increased insulin secretion, reduced glucagon secretion, delayed gastric emptying, and appetite suppression, thereby improving glycemic control and promoting weight loss."Just as an aside (and as a teaser) Dr. Julie Rodman will be giving a talk about the ocular effects of GLP1 analogs at CEwire2026.
More details to follow as the site goes live in a couple of weeks
-- ad
Yup, both are still low, relative to the effects of morbid obesity. Which is what these drugs really should be used for.Don't you mean absolute risk? The relative risk doubled, the absolute risk is small.
Yet obesity is behind most of the health issues we face as a nation, so obese patients will probably still come out ahead.Just as you Adam predict AI has problems as well as good I believe long term more and more problems and health concerns with emerge from GPL1 drugs. Yes they may help type II diabetics more then hurt but for the general population who take it to be stick figures watch out for those long term effects. You are changing basic function of the GI system " GLP-1, leading to increased insulin secretion, reduced glucagon secretion, delayed gastric emptying, and appetite suppression, thereby improving glycemic control and promoting weight loss."
Sounds good but let's wait a few years and see what may happen
Err even with the cost reductions Trump just put in most people who are obese still can't afford it especially if they are presumably on other meds which I would suspectYet obesity is behind most of the health issues we face as a nation, so obese patients will probably still come out ahead.
End point presumably is when you've lost enough weight until you're no longer type 2 / your HBA1c moves back into a normal range.Couple of things...read that the cost reductions applied to MR/MD programs...anyone hear about cost reductions to those not on MR/MD? Also, was surprised that the effect is short-term requiring continued usage and continued cost.
Is there an end point for GLP-1 usage or the same as metformin forever?
I have noticed that news anchors and entertainers that seemed to have healthy builds and were not obese, are now thin. People that are high wage earners that are constantly in the public spotlight. They likely have trainers and dieticians they have followed for decades, but now they have magically gone from "regular" to thin.End point presumably is when you've lost enough weight until you're no longer type 2 / your HBA1c moves back into a normal range.
The problem is going to be keeping the weight off long term without it.
Yep you can not be too rich or too thin. Money helps.So the rich get thinner.
I did not realize that. Wow.Women want girls rather then boys I guess. She sees school enrollments 70-75% female through IBF and genetic choice. It is noted in her kids classes in kindergarten and preschool so a recent trend